Better Therapeutics, Inc.
Better Therapeutics, Inc. (BTTX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · BTTX · as of Jun 8, 2026
Activity summary
Buy transactions
12
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Better Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
BTTX insider buying and selling by quarter
BTTX insider selling · BTTX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Recent insider transactions
BTTX executive sell shares · BTTX board member insider trading · BTTX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Feb 9, 2024 | PERRY DAVID P Executive Chairman · Director | Award | 839,895 | $160K | Form 4 |
| Jan 9, 2024 | PERRY DAVID P Executive Chairman · Director | Award | 1,471,453 | $250K | Form 4 |
| Dec 18, 2023 | PERRY DAVID P Executive Chairman · Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Carmona Richard H Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | LAVIZZO-MOUREY RISA J Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Wynholds Kristin Chief Product Officer | Award | 25,362 | — | Form 4 |
| Dec 18, 2023 | Parker Geoffrey M. Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Armanino Andrew J. Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | Miller Leslie A. PAO | Award | 3,587 | — | Form 4 |
| Dec 18, 2023 | Granger Elder Director | Award | 3,750 | — | Form 4 |
| Dec 18, 2023 | KARBE FRANK CEO · Director | Award | 62,500 | — | Form 4 |
| Dec 18, 2023 | Berman Mark A. Chief Medical Officer | Award | 25,362 | — | Form 4 |
| Jul 27, 2023 | PERRY DAVID P Executive Chairman · Director | Purchase | 1,233,045 | $900K | Form 4 |
| Jul 27, 2023 | Berman Mark A. Chief Medical Officer | Purchase | 54,802 | $40K | Form 4 |
| Jul 27, 2023 | Armanino Andrew J. Director | Purchase | 274,010 | $200K | Form 4 |
| Jul 27, 2023 | Granger Elder Director | Purchase | 34,251 | $25K | Form 4 |
| Jul 27, 2023 | KARBE FRANK CEO · Director | Purchase | 137,005 | $100K | Form 4 |
| Jul 27, 2023 | Parker Geoffrey M. Director | Purchase | 685,025 | $500K | Form 4 |
| May 16, 2023 | Granger Elder Director | Purchase | 600 | $520 | Form 4 |
| Apr 5, 2023 | Heinen Mark CFO | Award | 54,000 | — | Form 4 |
| Apr 5, 2023 | Wynholds Kristin Chief Product Officer | Award | 101,450 | — | Form 4 |
| Apr 5, 2023 | Berman Mark A. Chief Medical Officer | Award | 101,450 | — | Form 4 |
| Apr 10, 2023 | PERRY DAVID P See Remarks · Director | Purchase | 1,333,333 | $1.10M⚡ | Form 4 |
| Apr 10, 2023 | PERRY DAVID P See Remarks · Director | Purchase | 3,636,364 | $3.00M⚡ | Form 4 |
| Apr 10, 2023 | KARBE FRANK See Remarks · Director | Purchase | 242,424 | $200K | Form 4 |
PERRY DAVID P
Executive Chairman · Director
Date
Feb 9
Shares
839,895
Price
$0.19
Value
$160K
PERRY DAVID P
Executive Chairman · Director
Date
Jan 9
Shares
1,471,453
Price
$0.17
Value
$250K
PERRY DAVID P
Executive Chairman · Director
Date
Dec 18
Shares
3,750
Price
—
Value
—
PERRY DAVID P
Executive Chairman · Director
Date
Jul 27
Shares
1,233,045
Price
$0.73
Value
$900K
Berman Mark A.
Chief Medical Officer
Date
Jul 27
Shares
54,802
Price
$0.73
Value
$40K
PERRY DAVID P
See Remarks · Director
Date
Apr 10
Shares
1,333,333
Price
$0.82
Value
$1.10M ⚡
PERRY DAVID P
See Remarks · Director
Date
Apr 10
Shares
3,636,364
Price
$0.82
Value
$3.00M ⚡
KARBE FRANK
See Remarks · Director
Date
Apr 10
Shares
242,424
Price
$0.82
Value
$200K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About BTTX insider trading
BTTX insider trades
Better Therapeutics, Inc. (BTTX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including BTTX. Over the past 12 months, 0 insiders have filed transactions with the SEC. BTTX insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Better Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
BTTX insider trading · 5 questionsThe insiders of Better Therapeutics, Inc. (BTTX) include executives and directors such as BTTX, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026